Consensus for FY23 revenue $3.94B, according to Bloomberg. Reaffirms FY23 Adjusted EBITDA view $700M-$750M. This note updates a prior version to use Bloomberg’s consensus figures.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BLCO:
- BLCO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Bausch Health price target raised to $9 from $8 at RBC Capital
- Bausch + Lomb price target raised to $23 from $22 at Citi
- Bausch + Lomb buys J&J’s Blink eye and contact lens drops product line
- Bausch + Lomb price target raised to $23 from $19 at BofA